HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 07, July 2019 – Traditional Chinese medicine in modern healthcare — Integrating both worlds       » China approves norovirus vaccine for clinical trial       » AI offers breakthrough in cancer diagnosis       » Digital mental health strategy in China       » A wearable that's not to be laughed at       » Junk food could be responsible for the food allergy epidemic      
INSIDE INDUSTRY
Proteona releases CAR T characterisation product
Innovative genomic and proteomic analysis platform for cell therapy and immuno-oncology

Proteona announced the launch of its latest ESCAPE proteogenomics assay designed specifically for Chimeric Antigen Receptor (CAR) T cell characterisation.

This is the first commercial product designed to characterise both RNA and protein expression levels across thousands of single CAR T cells.

Through the use of simultaneous gene and protein expression analysis, the ESCAPE CAR T assay is able to identify CAR positive cells, measure changes in cytokine expression, deeply phenotype cells through measuring the expression of 25 key cell surface proteins and discover new gene expression patterns important for your research.

Together with Proteona鈥檚 data analysis support, the ESCAPE CAR T assay provides rich information that can be used at all stages of the CAR T workflow, from initial cell collection to post infusion patient monitoring.

The Proteona CAR T assay is based on the Enhanced Single Cell Analysis with Protein Expression (ESCAPE) RNA sequencing technology, which uses DNA-barcoded antibodies to capture proteomic and gene expression data simultaneously at the single cell level.

CAR T cells are a promising therapy against aggressive blood cancers and solid tumors. They are manufactured from T cells, immune cells that are able to recognize specific markers on pathogens or abnormal cells and destroy them.

To manufacture CAR T, human T cells are harvested and then modified to target specific cancer antigens, so that they are able to find and kill cancer cells once infused back to the patient. CAR T manufacturing is a complex process, and there is a large range of variations in patient response in terms of toxicity and efficacy.

It is still not clear what the mechanisms are that determine the safety and functionality of CAR T cell treatment. The new CAR T ESCAPE assay now provides a comprehensive tool to shed light on the complex CAR T mechanisms, opening a new path for the development of safer cell therapies.

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy